Related Experiment Video
Updated: Apr 14, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.7K
Pharmaceutical approval update
P & T : a Peer-Reviewed Journal for Formulary Management
|April 16, 2015
Abstract:
Nivolumab (Opdivo) for unresectable or metastatic melanoma; ombitasvir/paritaprevir/ritonavir with dasabuvir (Viekira Pak) for hepatitis C virus infection; and olaparib (Lynparza) for ovarian cancer.
Insights
Nivolumab, Viekira Pak, and olaparib show promise in treating advanced melanoma, hepatitis C, and ovarian cancer, respectively. These targeted therapies represent significant advancements in oncology and virology.
Area of Science:
- Oncology
- Virology
- Pharmacology
Background:
- Melanoma, hepatitis C virus (HCV) infection, and ovarian cancer pose significant global health challenges.
- Existing treatments for these conditions have limitations in efficacy and side effect profiles.
- Advancements in targeted therapies and drug combinations offer new treatment avenues.
Purpose of the Study:
- To evaluate the efficacy of nivolumab (Opdivo) in patients with unresectable or metastatic melanoma.
- To assess the effectiveness of ombitasvir/paritaprevir/ritonavir with dasabuvir (Viekira Pak) for hepatitis C virus infection.
- To determine the utility of olaparib (Lynparza) in the treatment of ovarian cancer.
Main Methods:
- Clinical trials were conducted to assess nivolumab's impact on melanoma progression.
- Patient cohorts received ombitasvir/paritaprevir/ritonavir with dasabuvir for HCV treatment.
- Olaparib was administered to patients diagnosed with ovarian cancer in clinical studies.
Main Results:
- Nivolumab demonstrated significant clinical benefit in unresectable or metastatic melanoma.
- Viekira Pak achieved high sustained virologic response rates in HCV-infected individuals.
- Olaparib showed promising outcomes in ovarian cancer patients, particularly those with specific genetic mutations.
Conclusions:
- Nivolumab is an effective treatment option for advanced melanoma.
- Viekira Pak provides a highly effective regimen for hepatitis C virus infection.
- Olaparib represents a valuable therapeutic option for ovarian cancer management.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
335
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
335
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
01:25Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
01:26Drug Administration and Therapy Phases: Overview
2.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.0K
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
360
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360